metformin has been researched along with Adenomatous Polyposis Coli, Familial in 2 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Park, JJ | 1 |
| Kim, BC | 1 |
| Hong, SP | 1 |
| Seo, Y | 1 |
| Lee, HS | 1 |
| Park, YS | 1 |
| Na, SY | 1 |
| Park, SC | 1 |
| Park, J | 1 |
| Kim, JH | 1 |
| Moon, CM | 1 |
| Huh, KC | 1 |
| Park, SJ | 1 |
| Cheon, JH | 1 |
| Kim, WH | 1 |
| Kim, TI | 1 |
| Walcott, FL | 1 |
| Patel, J | 1 |
| Lubet, R | 1 |
| Rodriguez, L | 1 |
| Calzone, KA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT01725490] | Phase 2 | 34 participants (Actual) | Interventional | 2013-02-15 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for metformin and Adenomatous Polyposis Coli, Familial
| Article | Year |
|---|---|
Hereditary cancer syndromes as model systems for chemopreventive agent development.
Topics: Adaptor Proteins, Signal Transducing; Adenomatous Polyposis Coli; Adenosine Triphosphatases; Animals | 2016 |
1 trial available for metformin and Adenomatous Polyposis Coli, Familial
| Article | Year |
|---|---|
The Effect of Metformin in Treatment of Adenomas in Patients with Familial Adenomatous Polyposis.
Topics: Adenomatous Polyposis Coli; Adult; Double-Blind Method; Duodenal Neoplasms; Female; Humans; Male; Me | 2021 |